| Identification | Back Directory | [Name]
9-Nitrocamptothecin | [CAS]
86639-62-5 | [Synonyms]
RUBETICAN
9-NITRO-CPT
9-Nitro-20(S)-camptothecine
CAMPTOTHECIN, 9-NITRO-20(S)-
10-Nitrocamptothecin ISO 9001：2015 REACH
4α-Ethyl-4-hydroxy-10-nitro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-4-Ethyl-4-hydroxy-10-nitro-1H-pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-di
(S)-4-Ethyl-4-hydroxy-9-nitro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-4-Ethyl-4-hydroxy-10-nitro-1H-pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-9-nitro-, (4S)- | [Molecular Formula]
C20H15N3O6 | [MDL Number]
MFCD06656294 | [MOL File]
86639-62-5.mol | [Molecular Weight]
393.35 |
| Hazard Information | Back Directory | [Uses]
Whether cells can divide depends on the two key points of entering S phase and M phase. Studies have found that 10-Nitrocamptothecin can induce apoptosis. After administration, both S phase and G2M phase of cell growth are delayed. Inhibition occurred throughout the cell cycle and was found to be dose- and time-dependent. | [Definition]
ChEBI:Rubitecan is a pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin. It has a role as an antineoplastic agent, an EC 5.99.1.2 (DNA topoisomerase) inhibitor and a prodrug. It is a pyranoindolizinoquinoline, a C-nitro compound, a semisynthetic derivative, a tertiary alcohol and a delta-lactone. |
|
|